miRNAs, from Evolutionary Junk to Possible Prognostic Markers and Therapeutic Targets in COVID-19

Viruses. 2021 Dec 27;14(1):41. doi: 10.3390/v14010041.

Abstract

The COVID-19 pandemic has been a public health issue around the world in the last few years. Currently, there is no specific antiviral treatment to fight the disease. Thus, it is essential to highlight possible prognostic predictors that could identify patients with a high risk of developing complications. Within this framework, miRNA biomolecules play a vital role in the genetic regulation of various genes, principally, those related to the pathophysiology of the disease. Here, we review the interaction of host and viral microRNAs with molecular and cellular elements that could potentiate the main pulmonary, cardiac, renal, circulatory, and neuronal complications in COVID-19 patients. miR-26a, miR-29b, miR-21, miR-372, and miR-2392, among others, have been associated with exacerbation of the inflammatory process, increasing the risk of a cytokine storm. In addition, increased expression of miR-15b, -199a, and -491 are related to the prognosis of the disease, and miR-192 and miR-323a were identified as clinical predictors of mortality in patients admitted to the intensive care unit. Finally, we address miR-29, miR-122, miR-155, and miR-200, among others, as possible therapeutic targets. However, more studies are required to confirm these findings.

Keywords: COVID-19; SARS-CoV-2; complications; miRNA; prognosis; therapeutic; virus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology
  • COVID-19 / complications
  • COVID-19 / diagnosis*
  • COVID-19 / genetics
  • COVID-19 Drug Treatment*
  • Drug Delivery Systems
  • Host-Pathogen Interactions / drug effects
  • Host-Pathogen Interactions / genetics
  • Humans
  • Inflammation
  • MicroRNAs / administration & dosage
  • MicroRNAs / genetics*
  • Prognosis
  • RNA, Viral / genetics
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / genetics

Substances

  • Antiviral Agents
  • MicroRNAs
  • RNA, Viral